Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes  
Phillip Home Send to Friends Free Subscription Give Comments 中文版
26 Mar, 2019 (Tuesday)



ESSEX BIO-TECH(1061)
Analysis:
ESSEX BIO-TECH is a leading ophthalmology and surgical drug manufacturer and promoter in China. Driven by the core patent drug bFGF, the company`s five-year revenue CAGR has increased by more than 20% annually, and the profit CAGR more than 30% annually. Since the launch of the “Enhancement Plan” in 2015, the company has successfully invested in different targets and cooperated in various markets. Recently, the company signed an agreement with Russian Mitotech to obtain the permanent commercialization rights of its third-phase clinical dry eye products in Singapore and Greater China at a price of up to US$37 million, while sharing global benefits. In addition, ESSEX BIO-TECH recently invested 8% stake in the company "Shanggong Yixin", which focuses on fundus screening and chronic disease management and has an AI fundus screening products "Huiyantangwang". In addition, the company recently launched the first single-dose levofloxacin eye drop product without preservatives.
Strategy:
Buy-in Price: $6.00, Target Price: $7.00, Cut Loss Price: $5.50


ETFMG Alternative Harvest ETF (MJ)
ETFMG Alternative Harvest ETF is a passively-managed ETF with market cap of approximately USD 1.01 billion and expense ratio of 0.75%. MJ is the first US-listed ETF to offer exposure to legal cultivation, production, marketing or distribution of cannabis products for either medical or nonmedical purposes. In October of 2018, Canada legalized cannabis for adult recreational use. In addition to Canada, about 10 U.S. states have legalized cannabis for recreational use while almost half the states approved cannabis for medicinal but not recreational uses. According to the BDS Analytics, global spending on global cannabis products may surge 40% in 2019 with estimated 18.1 billion. Estimated global sales should reach $32 billion by 2022 from $12.9 billion in 2018, which is a 25.5% compound annual growth rate. Due to the loosened rules and regulations, the US will become the major driving force for the growth of legal cannabis industry, followed by Canada. Increasing adoption of legalized cannabis in various products particularly medical and recreational use would further expand the cannabis industry. Therefore, investors can access the growth opportunity through MJ ETF. Recommend to buy at $37.3, target price $43.9, cut loss if drop below $32.9.



Cathay Pacific (293.HK) - 2018 result review: Turned from Loss to Profit

Investment Summary

The Year-round Result Turned from Loss to Profit and Earned HK$2.3 Billion Which Is Better Than Expected: Cathay Pacific recently reported its result. In 2018, it recorded a profit of HK$2.345 billion, compared with a loss of HK$1.259 billion in previous years, equivalent to a profit of about HK$0.596 per share, which was better than expected. The proposed second interim dividend is HK$0.2 per share and the total annual dividend is HK$0.3, a five-fold increase with a 50% dividend rate.

Fuel Costs Have Increased Rapidly, But Losses Have Been Greatly Reduced Due to Fuel Hedging: The fuel cost increased by 8.9% in the period due to a 28% increase in fuel price and a 1.6% increase in fuel consumption. The losses reduced by 77.3% due to fuel hedging and the increase was partly offset. In addition, the Company invested more fuel-efficient new models, which reduced fuel consumption by 1.9% per ton of revenue per kilometre.

Business Profits Expanded in H2: Since the second half of 2016, the Company has recorded three consecutive six-month operating losses. In H1, driven by a 15.7% yoy increase in total revenue and an 8.24% increase in operating expenses, the operating profit turned from negative to positive again, reaching HK$697 million. In H2, Cathay Pacific's total revenue and operating expenditure increased by 12.7% and 7.65%, respectively, while its operating profit increased to HK$2.898 billion, up by 316% compared with H1.

The Growth Rate of Financial Expenditure Has Shrunk, But the Contribution of Joint Ventures Has Declined Significantly: Compared with H1, the financial expenditure in H2 was basically flat, up by 16.6% or HK$1.57 billion yoy, reaching HK$1.104 billion, a sharp decrease from 24% in H1. However, the profits contributed by the joint ventures decreased by 37% or HK$784 million, reaching HK$1.313 billion, reflecting the decline of the results of Air China and Air China Cargo. In H2, the shareholders` share of the Company's profits soared by 229% yoy or HK$1.8 billion, reaching HK$2.61 billion.

The Continuous Improvement of Yield of Passenger Transport and Vigorous Cargo Demand Sustained in H2: The increase of passenger capacity of the Company (+3.78%) was faster than that of the number of passengers (+1.85%). The P L/F decreased slightly by 0.3 ppts to 84.1% yoy. Due to the improvement of revenue management, the increase of fuel surcharges, and the continuing strong demand for first class and business class, the increasing trend of yield of passenger continued in H2, and the yield of passenger rose 6.7% to HK$0.558 yoy. And overall yield of passenger transport increased by 10.1% to HK$73.12 billion.

The strong momentum of freight transport business was also continuing. The increased demand for special freight transport and transport of imports and exports of higher value goods of Asian routes drove the Company's freight transport yield from HK$1.93 in the middle of the year to HK$2.03 in the whole year and carriage rate from 68.3% to 68.8%. The growth rate of overall freight transport revenue accelerated from 16.3% in H1 to 18.5% in the whole year, reaching HK$28.316 billion.

Initial Results of the Transformation Plan: Management team said that the transformation plan was progressing satisfactorily. During this period, the Company restructured the head office's team structure and appointed a new management and leadership team to carry out a series of cost control measures, and achieved certain result. The basic cost per ton kilometre (except fuel) increased by only 1.9%, from HK$2.14 to HK$2.25. There is one year left for the three-year transformation plan. In order to enhance competitiveness, the Company will continue to expand its airline network to places where airlines in Hong Kong never arrived, add popular airline flights, and operate more fuel-efficient aircraft. It is reported that the Company plans to employ at least 2,000 additional staff this year, including crew, pilots and ground crew. We believe that this reflects the optimistic expectations of management for the future. By the end of last year, Cathay Pacific had employed more than 32,400 employees worldwide.

Investment thesis

Operational data in the first month of 2019 showed that passenger transport demand was satisfactory, but freight transport demand is lower than that in previous years. The prospect of global freight transport business is uncertain due to the impact of the progress of Sino-US trade negotiations. However, the Company's high value-added air freight will benefit from the prosperity of e-commerce and cross-border trade, as well as the upgrading of consumption of domestic middle class. Based on the revised financial forecast, we lift target price to HK$15.7 for the Company, equivalent to 2019/2020E 0.93/0.89x P/B, reaffirming the accumulate rating. (Closing price as at 22 March 2019)

Risk

Surging oil price

RMB depreciation

Demand affected by economy

Transformation program failed

Financials

Click Here for PDF format...




Recommendation on 26-3-2019
RecommendationAccumulate
Price on Recommendation Date$ 13.700
Suggested purchase priceN/A
Target Price$ 15.700
Writer Info
Zhang Jing
(Research Analyst)
Tel: (+86 21 51699400-103)
Email:
zhangjing@phillip.com.cn

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the “Group”) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products’ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

版權所有, 翻印必究。

Copyright(C) 2019 Phillip Securities (HK) Ltd. All Rights Reserved.